Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Advanced glycation end products (AGEs) are a group of compounds, which are formed by non-enzymatic reactions between carbonyl groups of reducing sugars and free amino groups of proteins, lipids or nucleic acids and can be obtained exogenously from diet or formed endogenously within the body. AGEs accumulate intracellularly and extracellularly in all tissues and body fluids and can cross-link with other proteins and thus affect their normal functions.

The global advanced glycation end products market is estimated to be valued at US$ 1,368.5 million in 2020 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020-2027).

Figure 1. Global Advanced Glycation End Products Market Share (%), By Region, 2019

Advanced Glycation End Products  | Coherent Market Insights

Increasing cases of cancer is expected to propel the market growth over the forecast period

The increasing number of cancer cases worldwide is expected to boost the market growth, as AGEs significantly increase the level of inflammation in the body which has long been associated with the development of cancer. For instance, according to the National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024 in the U.S.

Similarly, according to the American Cancer Society, 2015, an estimated 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer death.

request-sample

Advanced Glycation End Products Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,368.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.3% 2027 Value Projection: US$ 2,130.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Non-fluorescent AGEs, Fluorescent AGEs.
  • By Application: Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, Others.
  • By End User: Hospitals, Specialty Clinics, Homecare Settings.
Companies covered:

Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, and Rodan & Fields, LLC

Growth Drivers:
  • Increasing product approvals and launches
  • Increasing number of aesthetic procedures
  • Increasing collaborations, acquisitions, and partnerships
Restraints & Challenges:
  • High cost of aesthetic procedures

 Figure 2. Global Advanced Glycation End Products Market Share (%), by Type, 2020

Advanced Glycation End Products  | Coherent Market Insights

Increasing cases of neurodegenerative diseases is expected to drive the market growth over the forecast period

Increasing cases of neurodegenerative diseases such as Alzheimer’s, Parkinson’s diseases, and other are expected to drive the market growth over the forecast period, as AGEs are proteins and glycated after exposure to sugars that is contribute to the development of neurodegenerative diseases.  For instance, according to the World Alzheimer Report 2015 published by Alzheimer’s Disease International (ADI), in 2015 the new dementia cases in the regions were 4.9 million (49.0%) in Asia, 2.5 million (25.0%) in Europe, 1.7 million (18.0%) in the Americas, and 0.8 million (8.0%) in Africa. Furthermore, according to the Parkinson's UK, in 2015 there were around 137,000 people suffered from Parkinson’s in the U.K.

Global Advanced Glycation End Products Market – Impact of Coronavirus (Covid-19) Pandemic

Advanced glycation products (AGEs) resulting from the fixing of sugars on proteins, create cross links which definitively reduce the elasticity of elastin used in the aesthetic procedures. The American Society of Plastic Surgeons has recommended to postpone all the elective or non-essential services due to which the number of aesthetic procedures such as chemical peel, botulinum toxin therapy, dermabrasion, and others have decreased hindering the advanced glycation end products market growth. According to the article published in the Aesthetic Journal on April 03, 2020, around 81% of clinics are closed and 67% are experiencing reduction in revenue due to the COVID-19 lockdown in London.

Furthermore, several skincare and cosmetic companies are observing a decline in sales due to the COVID-19 pandemic. For instance, on May 12, 2020, Shiseido Company, a Japan-based multinational personal care company, released its financial statement for the first quarter of 2020 reporting a 14.6% and 19.2% year-on-year net sales decline in the American and Asia Pacific business, respectively.

Advanced Glycation End Products Market Restraint

High cost of aesthetic procedures is expected to hinder the market growth over the forecast period. According to the American Society of Plastic Surgeons, the average cost of botox treatment is US$ 397 in the U.S. while a single session of microdermabrasion costs around US$ 131 and the cost of chemical peel is around US$ 669.

Key Players

Major players operating in the global advanced glycation end products market include Allergan Plc, Estée Lauder Companies, Shiseido Company, Beiersdorf AG, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc, Alma Laser, Rodan & Fields, LLC, and others.

Advanced glycation end products (AGEs), also known as glycotoxins or atherogenic molecules, are the diverse group of highly oxidant compounds. AGEs are formed through a non-enzymatic reaction between reducing sugars and free amino groups of proteins, lipids, or nucleic acids. This reaction is also known as the Maillard or browning reaction. Advanced glycation end products (AGEs) are used to treat pathological conditions such as diabetes mellitus (DM), cardiovascular disease, Alzheimer’s disease, cancer, and natural aging. Increasing prevalence of cardiovascular diseases (CVD) is expected to drive growth of the advanced glycation end products market. According to the American Heart Association, 2016, cardiovascular diseases account for 17.3 million deaths every year, globally, where an estimated 23.3 million people are expected to die from CVD by 2030. Such rising prevalence of chronic diseases is expected to drive the advanced glycation end products market growth over the forecast period. 

Market Dynamics

Market players are focusing on research and development of advanced glycation end products in diabetic complications as advanced glycation end products (AGEs) are key factor in the development of metabolic memory in diabetic complications, which is expected to drive growth of the global advanced glycation end products market over the forecast period. According to the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

Key features of the study:

  • This report provides in-depth analysis of the global advanced glycation end products market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global advanced glycation end products market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global advanced glycation end products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global advanced glycation end products market

Detailed Segmentation:

  • Global Advanced Glycation End Products Market, By Type:
    • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
    • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
  • Global Advanced Glycation End Products Market, By Application:
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
  • Global Advanced Glycation End Products Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
  • Global Advanced Glycation End Products Market, By Region:
    • North America
      • By Type:
        • Non-fluorescent AGEs
          • Carboxymethyl-lysine (CML)
          • Carboxyethyl-lysine (CEL)
          • Pyrraline
        • Fluorescent AGEs
          • Pentosidine
          • Methylglyoxal-lysine dimer (MOLD)
      • By Application
        • Diabetic Complications
        • Cancer
        • Bone Diseases
        • Neurodegenerative Diseases
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings 
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Non-fluorescent AGEs
          • Carboxymethyl-lysine (CML)
          • Carboxyethyl-lysine (CEL)
          • Pyrraline
        • Fluorescent AGEs
          • Pentosidine
          • Methylglyoxal-lysine dimer (MOLD)
      • By Application
        • Diabetic Complications
        • Cancer
        • Bone Diseases
        • Neurodegenerative Diseases
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Non-fluorescent AGEs
          • Carboxymethyl-lysine (CML)
          • Carboxyethyl-lysine (CEL)
          • Pyrraline
        • Fluorescent AGEs
          • Pentosidine
          • Methylglyoxal-lysine dimer (MOLD)
      • By Application
        • Diabetic Complications
        • Cancer
        • Bone Diseases
        • Neurodegenerative Diseases
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Non-fluorescent AGEs
          • Carboxymethyl-lysine (CML)
          • Carboxyethyl-lysine (CEL)
          • Pyrraline
        • Fluorescent AGEs
          • Pentosidine
          • Methylglyoxal-lysine dimer (MOLD)
      • By Application
        • Diabetic Complications
        • Cancer
        • Bone Diseases
        • Neurodegenerative Diseases
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Non-fluorescent AGEs
          • Carboxymethyl-lysine (CML)
          • Carboxyethyl-lysine (CEL)
          • Pyrraline
        • Fluorescent AGEs
          • Pentosidine
          • Methylglyoxal-lysine dimer (MOLD)
      • By Application
        • Diabetic Complications
        • Cancer
        • Bone Diseases
        • Neurodegenerative Diseases
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Non-fluorescent AGEs
          • Carboxymethyl-lysine (CML)
          • Carboxyethyl-lysine (CEL)
          • Pyrraline
        • Fluorescent AGEs
          • Pentosidine
          • Methylglyoxal-lysine dimer (MOLD)
      • By Application
        • Diabetic Complications
        • Cancer
        • Bone Diseases
        • Neurodegenerative Diseases
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Homecare Settings
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Merck KGaA*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Diagnoptics Technologies B.V
    • Cell Biolabs, Inc.
    • Shanghai Korain Biotech Co., Ltd
    • Scent-Sations, Inc.
    • I. de la Nau
    • KOKEN CO., LTD.

“*” marked represents similar segmentation in other categories in the respective section.       

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Advanced Glycation End Products Market – Impact of Coronavirus (COVID-19) Pandemic
    • Impact assessment
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Government measures to combat COVID-19
  5. Global Advanced Glycation End Products Market, By Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Non-fluorescent AGEs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Carboxymethyl-lysine (CML)
        • Carboxyethyl-lysine (CEL)
        • Pyrraline
    • Fluorescent AGEs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Pentosidine
        • Methylglyoxal-lysine dimer (MOLD)
  6. Global Advanced Glycation End Products Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Diabetic Complications
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Bone Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Neurodegenerative Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Advanced Glycation End Products Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Home Care Settings
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Advanced Glycation End Products Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Merck KGaA
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Diagnoptics Technologies B.V.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cell Biolabs, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Shanghai Korain Biotech Co., Ltd 
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Scent-Sations, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • I. de la Nau
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • KOKEN CO., LTD. 
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 25 market data tables and 20 figures on “Advanced Glycation End Products Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global advanced glycation end products market size is estimated to be valued at US$ 21.06 billion in 2019 and is expected to exhibit a CAGR of 7.3% between 2020 and 2027.
The increasing launches of advanced glycation end products, increasing number of chronic diseases, research and development in advanced glycation end products by major players, and increasing geriatric population are driving the Advanced Glycation End Products market growth.
Non-fluorescent AGEs segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America advanced glycation end products market is expected to generate highest revenue share during the forecast period.
Major factors hampering growth of the market include high cost of cosmetic procedures.
Major players operating in the global advanced glycation end products market include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others. .
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner